NCT Number: NCT05504057
The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.
Interested in participating?
Request InfoAll sexes
Observational
Hospital de Terrassa, Terrassa, Barcelona, Spain
BACKGROUND: According to previous reports, all 84 eldery residents in nuersing homes in Yespes (Toledo, Spain), had a 100% of positive serology for COVID-19 in June 2020, but none died nor hospitalized after receiving early treatment with antihistamines. Other case reports have suggested a protective role of amantadine, since infected patients showed a very mild COVID19 infection.
OBJECTIVES.Determine the role of antihistamines and amantadine in the evolution of COVID19.
METHODS. Describe the rate of hospitalization, ICU, survival, postcovid syndrome and thrombosis among COVID 19 cases having antihistamines and amantadine as chronic treatments.
The rates would be stratified by age groups and compared with the same age groups of the population assigned to the public free Access Terrassa Health Consortium.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients having chronic treatment with antihistamines or amantadine -
Exclusion criteria
None
-
Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and postcovid syndrome and thrombosis among patients previously treated with antihistamines
Other names: Antihistamine as crhonic treatment and COVID19 infection.
Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and the rate of postcovid syndrome and thrombosis among patients previously treated with amantadine
Other names: Amantadine as chronic treatment and COVID19 infection.
Time frame: from march 2020.
Rate of Hospitalization among COVID 19 infections
Time frame: from march 2020
Survival among COVID1 hospitalized cases.
Time frame: from march 2020
Patients suffering a symptomatic COVID19 infection within a determinate age group
Time frame: from april 2020
Patients developing postcovid syndrome after COVID19 infection
Time frame: from april 2020
Patients developing thrombosis (with particular assessment of stroke, cardiac infarction, retinal vessels and pulmonary embolism)
Contact information is provided by the study sponsor or research team.
Consorci Sanitari de Terrassa
Other
Evaluation of Treatments With Antihistamines and Amantadine in the Evolution of the SARS-CoV-2 Infection
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05787327
COVID-19, Coronaviridae Infections
Hong Kong
View Trial DetailsNCT07536308
COVID-19, Coronaviridae Infections
Decatur, Georgia, United States
View Trial DetailsNCT01306084
Adenoviridae Infections, Anogenital Herpes
Bethesda, Maryland, United States
View Trial DetailsNCT04330599
COVID-19, Coronaviridae Infections
London, County (optional), United Kingdom
View Trial Details